Patents Assigned to Supramol Parenteral Colloids GmbH
  • Patent number: 7932377
    Abstract: A molecular complex of a high molecular weight carrier substance and of a medicinal substance. The carrier substance has functional groups whereby the carrier substance and the medicinal substance are bound non-covalently. The medicinal substance is insoluble or slightly soluble in water and the carrier substance is readily soluble in water. The carrier substance can be starch or a starch derivative and can have only one functional group for non-covalent binding of the medicinal substance in each molecule.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: April 26, 2011
    Assignee: Supramol Parenteral Colloids GmbH
    Inventor: Klaus Sommermeyer
  • Publication number: 20090281296
    Abstract: The present invention relates to a process for the production of a conjugate from a polynucleotide and a polysaccharide comprising the steps: a) provision of an aldonic acid of the polysaccharide or of a derivative thereof; b) reaction of the aldonic acid with an alcohol derivative, preferably a carbonate derivative of an alcohol, to an aldonic acid ester, preferably to an activated aldonic acid ester; and c) reaction of the aldonic acid ester with the polynucleotide, wherein the polynucleotide exhibits a functional amino group, wherein the reaction of the aldonic acid with the alcohol derivative in step b) takes place in a dry aprotic polar solvent.
    Type: Application
    Filed: February 8, 2005
    Publication date: November 12, 2009
    Applicants: Supramol Parenteral Colloid GMBH, Noxxon Pharma AG
    Inventor: Klaus Sommemeyer
  • Patent number: 7393841
    Abstract: The invention relates to the use of hyperbranched amylopectin which has an average branch degree of between >10 and 25 mol % and a molecular weight (Mw) ranging from 40.000-800.000 Dalton and the derivatives thereof in methods for surgical or therapeutic treatment of human or animal bodies or in a diagnostic method, preferably as a plasma volume expander. Plasma volume expanders based on hydroxy-ethylated amylopectin have, as a result of hydroxy ethylation, hitherto exhibited the disadvantage of incomplete metabolism and thus temporary tissue storage which is linked to side-effects. According to the invention, novel plasma expanders based on polysaccharides which do not exhibit the same disadvantages as the former are provided.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: July 1, 2008
    Assignee: Supramol Parenteral Colloids GmbH
    Inventor: Klaus Sommermeyer